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Abstract
Background: Pituitary adenomas are benign brain tumors that cause considerable morbidity and neurological
symptoms. SOX9 as a regulatory transcriptional mediator affects normal and tumor cell growth with an undefined
role in pituitary adenomas pathogenesis. Thus, in the present study, the expression pattern of SOX9 in GH-secreting
pituitary tumors and normal pituitary tissues is investigated.
Methods: The SOX9 gene expression level was evaluated in 60 pituitary tissues including different types of GH-
secreting adenomas and normal pituitary tissues through Real-Time PCR. The protein level of SOX9 was assessed
using immunohistochemistry. The correlations of SOX9 gene and protein expression level with the patient’s clinical
and pathological features were considered.
Results: The SOX9 over-expression was detected in GH-secreting adenomas tumor tissues compared to normal
pituitary tissues which were accompanied by overexpression of SOX9 protein in tumor tissues. The over-expression
of SOX9 had a significant impact on GH-secreting adenomas tumor incidence with the odds ratio of 8.4 and the
diagnostic value of SOX9 was considerable. The higher level of SOX9 expression was associated with invasive and
macro tumors in GH-secreting pituitary adenoma patients. The positive correlation of SOX9 gene and protein level
was observed and the tumor size and tumor invasive features were valuable in predicting SOX9 expression level in
GH-producing pituitary tumors.
Conclusion: The study provided the first shreds of evidence regarding the expression pattern of SOX9 in the GH-
secreting pituitary adenomas at both gene and protein levels which may emphasize the possible involvement of
SOX9 as a mediator in pituitary adenoma tumor formation also open up new intrinsic molecular mechanism
regarding pituitary adenoma pathogenesis.
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Background
Among the intracranial brain tumors, pituitary aden-
omas are common, complex, and multifactorial tumors
that impose a great burden of morbidity on patients
worldwide [1]. Growth hormone (GH)-secreting aden-
oma belongs to the hormone-secreting pituitary aden-
omas with insidious and debilitating clinical presentation
ranging from calcium-phosphate alteration, the elevation
of bone turn over, coarse facial features, and growth hor-
mone over production [2, 3]. Most recently, the GH-
secreting adenoma prevalence was reported as 2–13/
100000 in the population with the approximate equal
rate of incidence in males and females that mostly diag-
nosed over the age of 50. The clinical manifestations of
patients besides excess growth hormone and Insulin-like
growth factor-1 (IGF-I) levels are attributed to the diag-
nosis of the disease [4]. However, the diagnostic delay
and limited early diagnosis in those patients lacking the
main clinical features of GH-secreting adenoma likewise
acral enlargement or those who suffer from overlapped
conditions, make the disease consequences even more
deleterious [5, 6]. The aberrant GH-producing cell pro-
liferation in the anterior pituitary gland caused tumor
formation which is mostly categorized as macroadenoma
and triggers acromegaly clinical demonstrations [4, 7].
Accordingly, evidence revealed that pituitary tumor for-
mation can be influenced by cancer stem cell (CSC)
population likewise the presence of progenitor mesen-
chymal cells (PMCs) as CSC derivatives in GH-secreting
adenoma and hormone in-active pituitary tumors [8–
10]. Notably, the higher percentages of endothelial pro-
genitor cells (EPCs) in the GH-secreting adenoma pa-
tients and their correlation with IGF-1was meaningful
[11]. The sex-determining region Y-box 9 (SOX9) is a
multi-functional transcription factor that is involved in
tissue organogenesis, cell development, chondrogenesis,
cell differentiation through its ability to direct cells to
the specific lineage [12]. Regarding the notion of cancer
stem cells (CSCs) which ease the cell re-newel and dif-
ferentiation, recently SOX9 proposed as a CSC marker
due to its ability to maintain cells in the undifferentiated
status [13]. Notably, the correlation of SOX9 with cellu-
lar signaling pathway likewise NOTCH and Wnt, spot-
ted this transcription factor as an appealing effector
tumor cell fate [14]. The overexpression of SOX9 was
reported in some types of malignancies such as meta-
static melanoma [15] non-small cell lung cancer [16],
prostate cancer [17], and esophageal squamous cell car-
cinoma [12]. It was shown that SOX9 beside the estro-
gen receptor mediates transcription of the collagen gene
following stimulation of 17β-estradiol and induces chon-
drogenesis [18]. The feedback circuits between SOX9,
Foxa2, and Tcf2 coordinate a network leading to the
pancreatic progenitor cell programming and liver
organogenesis [19]. In light of the SOX9 regulatory role
in progenitor cell differentiation, it was revealed that fol-
lowing activation of SOX9 through the Notch pathway,
it can activate the expression of downstream mediators
mainly neurogenin 3, and induce pancreatic endocrine
differentiation [14]. The presence of stem cells in the pi-
tuitary gland contributes to both pituitary organ regen-
eration also flexible differentiation to specific hormone-
secreting cells in response to the body requirement [8].
Recent evidences are in favor of connecting pituitary
stem cells to the process of pituitary tumor cell forma-
tion, growth, and development [20]. Given the potential
role of SOX9 in tissue regeneration as well as its rele-
vance to the intracellular pathways regulating tumor cell
growth, this study is aimed to evaluate the status of
SOX9 in tumor tissues of GH- secreting pituitary aden-
omas at both gene and protein level to provide pieces of
evidence regarding the relevance of this effector with pi-
tuitary tumors. We applied both tumors and healthy tis-
sues of the pituitary to provide a clear comparison.
Methods
Patients and sample collection
A total number of 60 pituitary samples including 40
GH-producing pituitary adenomas and 20 cadaveric
healthy pituitary tissues were enrolled in the current
study with local ethical approval and informed consent.
The project was ethically approved by the ethics com-
mittee of the vice president of research at Iran Univer-
sity of Medical Sciences. Patients with GH-producing
pituitary adenomas were enrolled from January 2017 to
May 2019 and patients with a known history of any ma-
lignancy were excluded from the study. Also, to avoid
the possible effect of pituitary adenomas medical treat-
ments on SOX9 expression, only patients who have re-
ceived no treatments before surgery were selected and
enrolled in this study. All patients had been diagnosed
by imaging and post-surgery pathology also patients re-
ceived no radiotherapy before surgery when we took the
samples. In this study, the patients subjected to the
endoscopic transnasal transsphenoidal surgery (ETSS) at
the neurosurgery department of our institute were par-
ticipated and following surgical resection. Tumor sam-
ples were obtained and divided into two sections as
follows, one part was transferred to the pathology de-
partment for further histological evaluations and the rest
were immediately transferred to the lab in a cool situ-
ation for further evaluations. The healthy pituitary tis-
sues were collected from the Legal Medicine
Organization (LMO), Tehran, Iran at the first hour of
their death. The total number of 20 human healthy pitu-
itary autopsies was collected from cases with no patho-
logical pituitary problems from January 2017 to May
2019. The anterior epithelial lobe of pituitary tissues was
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selected without histological evidence of pathological fea-
tures. Normal pituitary autopsies were matched to the en-
rolled patients as a matter of age and gender. The mean
healthy donor’s age range was 46.52 ± 0.3 and an equal
number of male and female donors participated in the
study. Also, 85% of healthy donor’s Body mass index
(BMI) was ≤25 while 15% was over 25. The tumor and
normal pituitary sample collection and processing was
followed as our previous studies [21, 22]. The clinic-
pathological features of patients with pituitary adenoma
are summarized in Table 1. As is mentioned, amongst the
patients with GH- pituitary adenomas, 55% of the patients
were female and 45% were male, also the invasive feature
of the tumor was detected in 35% of patients while the
non-invasive tumor was diagnosed in 65% of patients It
should be noticed that invasive pituitary tumors were clas-
sified based on Knosp classification system in which
tumor extension to the adjacent sphenoid sinus and cav-
ernous sinus is defined as invasive tumor and also, con-
firmed by the neurosurgeon during the endoscopic
surgery. Based on our patient’s characters, the mean
tumor size of the patients was 14.25 ± 1.43 that the type of
tumor in 70% of our patients was macroadenoma but in
30% of patients the tumor type was microadenoma. Not-
ably, in our study, the tumor body greater than 10mm in
size was considered as macroadenomas and the tumor
body less than 10mm in size was defined as microadeno-
mas. Additionally, the mean patient’s age was 47.88 ± 4.2
which 42.5% of our patients were below 40 years of age,
while 57.5% were over 40 years of age, respectively. Also,
32.5% of healthy donor’s body mass index (BMI) was ≤25
while 67.5% of patients had BMI over 25. The statistical
analysis regarding participants ‘age, gender and, BMI re-
vealed that the difference between the BMI of patients
and healthy controls was statistically significant. The pa-
tient’s biochemical features and hormone levels were
assessed and summarized in Table 2.
RNA extraction, cDNA synthesis, real-time PCR
To evaluate the expression level of SOX9, the tissue
RNA was extracted and subjected to assessment via
Real-Time PCR. Accordingly, the RNA content of tumor
and healthy pituitary tissues were extracted using Trizol
(Invitrogen, Grand Island, USA) based on the manufac-
turer’s instructions. Briefly, tissues were lysed and ho-
mogenized with 700 μL of Trizol lysis reagent and
following an adequate incubation period, chloroform
was added to each tissue homogenate for subsequent
phase separation. The upper, aqueous phase was col-
lected and transferred to the new tube and mixed with
isopropanol. After an appropriate incubation time and
centrifugation, the supernatant was discarded and the
RNA pellet washed with 75% ethanol. The RNA pellet
was air-dried and dissolved in an appropriate volume of
RNase-free water. The extracted RNA of each tissue was
evaluated as a point of quality and quantity with a Nano-
drop spectrophotometer (Nanodrop Technologies). The
total amount of 1 μg of RNA was applied for cDNA Syn-
thesis via PrimeScript First Strand cDNA Synthesis Kit
(Takara, Japan) according to the manufacturer’s instruc-
tions. The gene expression was assessed via Real-Time
PCR using the SYBR Premix Ex Taq II (Takara, Japan)
via Applied Biosystems Step One Plus, Real-time system
(Applied Biosystems, USA). The expression running
time and program was as follow: 1 cycle at 95 °C for 5
min following 40 cycles at 95 °C for 5 S, 55 °C for 20 S,
and 60 °C for 35 S. Beta-actin was used as a housekeep-
ing gene for SOX9 gene expression normalization due to
its constitutive expression pattern in the pituitary gland
that was applied in previous reports [23–25]. The for-
mula RQ = 2-ΔCT was used to analyze the relative gene
expression levels after normalization with the endogen-
ous controls and the SOX9 and beta-actin melt curves
were considered as primer specificity. The sequence and
characters of primers were as: SOX9 forward primer:
Table 1 The clinicopathological features of patients with GH-producing pituitary adenoma
Parameter Groups Patients (N, %) Healthy subjects (N, %) P-Value
Age at diagnosis (Years) ≤40 17 (42.5%) 10 (50%) 0.5820
40≤ 23 (57.5%) 10 (50%)
Gender Female 22 (55%) 10 (50%) 0.7874
Male 18 (45%) 10 (50%)
Body mass index (BMI) ≤25 13 (32.5%) 17 (85%) 0.0003
25≤ 27 (67.5%) 3 (15%)
Tumor invasiveness a Invasive 14 (35%)
Non- Invasive 26 (65%)
Tumor sizeb Micro-Adenoma 10 (30%)
Macro-Adenoma 30 (70%)
a The definition of invasive tumor is presented in “Patients and sample collection” section
b The definition of macro/micro adenoma is presented in “Patients and sample collection” section
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5′– GCTTCTCGCTCTCGTTCAGA-3′, SOX9 reverse
primer: 5′-CAACGGCTCCAGCAAGAACA − 3′ (Tm =
58), beta-actin forward primer: 5′-GAT CTC CTT CTG
CAT CCT GT-3′, beta-actin reverse primer: 5′-TGG
GCA TCC ACG AAA CTA C- 3′ (Tm = 57).
Immunohistochemistry
The 4 μm tissue section of 40 paraffin-embedded pituit-
ary adenoma samples were applied for immunohisto-
chemistry analysis using an anti- SOX9 monoclonal
antibody (Cell Signaling, the Netherlands) as the primary
antibody. The slides were subjected to de-paraffinization
and rehydration, subsequently followed by getting
immersed in methanol containing 0.3% hydrogen perox-
ide for 20 min to inhibit peroxidase activity endogen-
ously. The antigen retrieval was performed using citrate
buffer incubation for 10 min. The dilution of 1:400 of
the primary antibody of SOX9 was applied following
proper incubation; the secondary antibody (Cell Signal-
ing, the Netherlands) was added afterward. To visualize
the antigen/antibody reaction the 3, 3′-diaminobenzi-
dine (DAB, Dako) was used. The slide scoring was
assessed by two independent pathologists who were
blinded to the data and discrepancies between them
were resolved by consensus. Based on the antibody in-
cluded protocol the colon cancer tissue was taken as a
positive control. For evaluation of SOX9 immunoreactiv-
ity, the results were divided into four graded according
to the percentages of positive cells and staining intensity
as follows: 0; less than 5% of neoplastic cells were
stained indicating absence of immunoreactivity, 1+; 5–
25% of neoplastic cells were stained indicating weak in-
tensity staining, 2+; 26–50% of neoplastic cells were
stained indicating moderate intensity staining, and 3+;
more than 50% of neoplastic cells were stained indicat-
ing strong intensity of staining. Depending on the cellu-
lar density of the tumor, the number of tumor cells
ranged from 200 to 300 cells per field that assessed in in
five different hot spot areas [26, 27].
Statistical analysis
For gene expression analysis the comparative CT (2-ΔCt)
method was applied wherein ΔCt corresponds to the Ct
of the SOX9 subtracted from the Ct of the endogenous
gene (Beta-Actin). The Kolmogorov-Smirnov analysis
was applied to determine the normal distribution of data
in patients and normal groups. Due to the normal distri-
bution, a t-test was used to analyze the difference be-
tween the expression of SOX9 between pituitary tumor
and normal tissues. The receiver operating characteristic
(ROC) curves and calculation of area under the curve
(AUC) were used to determine the diagnostic value of
SOX9 expression in tumor and normal tissue [28, 29].
To categorize the SOX9 expression level, a cut-off value
was determined using receiver operating characteristic
(ROC) analysis. A cut-off value was indicated as the
value of SOX9 that maximized the sensitivity and speci-
ficity of the discrimination between pituitary tumor and
normal tissue based on the Youden Index [28]. Tumor
tissues with SOX9 expression levels below the cut-off
were classified as low expression tumors, and those with
SOX9 expression levels above the cut-off were classified
Table 2 The biochemical features of patients with GH-producing pituitary adenoma
Parameters Normal range Standard deviation ± Mean
Blood Sugar (mg/dl) Normal: 100–145 156.1 ± 13.2
Alkaline phosphatase (U/L) Normal: Male 80–306
Female 64–306
228.5 ± 23.7
Calcium (Serum) (mg/dL) Normal: 8.6–10.3 141 ± 13.8
Sodium (Serum) (mmol/L) Normal: 136–145 142.4 ± 1.13
Inorganic Phosphorus (mg/dL) Normal: 2.7–4.5 5.8 ± 0.83
Potassium (mmol/L) Normal: 3.5–5.5 4.04 ± 0.11




Growth Hormone (ng/ml) Women:0.126–9.88 Men:0.03–2.47 14.71 ± 5.01
6.64 ± 2.3
ACTH (pg/ml) 7.2–63.3 40.49 ± 7.18
Cortisol (μg/dl) 6.2–19.4 21.20 ± 5.5





Age 47.88 ± 4.2
Tumor size 14.25 ± 1.43
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as high expression. The chi-square test was performed
to calculate the correlation of SOX9 expression levels
(i.e., low or high expression) with patients’ clinicopatho-
logical characteristics (age, gender, Body mass index
(BMI), tumor size, and invasive status). The association
and possible impact of SOX9 expression as a risk factor
for GH-secreting pituitary adenoma was calculated using
the odds ratio [30]. The regression analysis was applied
to determine the value of the variables in predicting
SOX9 expression level in tumors. The correlation be-
tween SOX9 gene expressions with SOX9 protein im-
munohistochemistry intensity staining also Ki67 labeling
index was analyzed using Pearson coefficient test in pa-
tients with GH-producing pituitary adenoma. The enu-
meration data are presented as percentages. Between-
group comparison of enumeration data, the chi-square
test was used. The Graph Pad Prism version 6 (Graph
Pad Software, San Diego California) and Statistical Pack-
age for Social Science (SPSS v.20) were used for the cal-
culation of all statistics. P values < 0.05 (two-sided) were
considered statistically significant.
Results
The expression level of SOX9 was increased in GH-
secreting pituitary adenoma
According to our data, the SOX9 expression level was
enhanced significantly in tumor tissues comparing to
normal pituitary tissues (P = 0.019) (Fig. 1). The mean
and standard error mean (SEM) of SOX9 mRNA level
was 0.66 ± 0.020 and 0.28 ± 0.105 in patients and control
group, respectively. The SOX9 expression was detected
around 2.3 times more in tumor tissues comparing to
healthy pituitary tissues. Moreover, to determine the
strength of association between SOX9 tumor expression
level and GH- secreting pituitary adenoma, the odds ra-
tio was calculated that it was revealed that SOX9 tumor
expression level significantly affect adenoma incidence
by the odds ratio of 8.4 (P = 0.015) (Table 3). To
categorize the SOX9 expression, the receiver operating
characteristic (ROC) curve was applied and a cut-off
value was determined. The value with the maximized
sensitivity and specificity was selected as a cut-off that
was able to discriminate between tumor and normal pi-
tuitary adenoma. The tumors with SOX9 expression
level below the cut-off value were defined as low expres-
sion tumors and the tumors with the SOX9 expression
level over the cut-off value were categorized as high ex-
pression levels. Based on our data, the ROC curve of
SOX9 expression in GH-producing pituitary tumor and
normal pituitary tissues revealed the AUC level of 0.755
(95% CI, 0.599–0.911, P = 0.007) with the best cut off
value of 0.54 which has 84.5 and 60% sensitivity and spe-
cificity, respectively based on the Youden Index (Fig. 2).
As is shown in Table 4, 58.82% of patients below 40
years of age revealed a low expression level of SOX9,
while 41.17% of them expressed a higher level of SOX9.
Also, 43.47 and 56.52% of patients over 40 years of age
showed a low and high levels of SOX9 expression, re-
spectively. Based on data presented here, the correlation
of age with SOX9 tumor expression was not significant
in GH- secreting pituitary adenoma patients. Besides,
54.54% of female patients expressed a low SOX9 level
while 45.45% of them expressed a high level of SOX9 in
tumor tissues. However, 44.44 and 55.55% of male pa-
tients with GH- secreting pituitary adenoma tumors pre-
sented low and high SOX9 expression levels,
respectively. In accordance, the patient’s gender showed
Fig. 1 The SOX9 expression level in GH-secreting pituitary
adenomas. The expression level of SOX9 was assessed in GH-
secreting pituitary tumors and normal pituitary tissues. The SOX9
gene expression level was elevated in GH-secreting pituitary
adenoma. The Statistical differences between groups are shown as
an asterisk (* = P < 0.05)
Table 3 Associations between SOX9 expression and GH-
producing pituitary adenoma
B S.E. Wald df P
value
Exp(B) 95% C.I.for EXP(B)
Lower Upper
SOX9 2.134 0.874 5.966 1 0.015 8.451 1.525 46.84
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Fig. 2 The SOX9 gene expression ROC Curve. The SOX9 gene expression ROC Curve, area under the curve, 95% confidence interval, P-value
is shown
Table 4 Associations between SOX9 expression and clinicopathological features of the patients
Parameter Groups SOX9 expression P-
ValueHigh expression Low expression
% N % N
Age (Years) ≤40 41.17% 7 58.82% 10 0.52
40≤ 56.52% 13 43.47% 10
Gender Female 45.45% 10 54.54% 12 0.75
Male 55.55% 10 44.44% 8
Tumor invasiveness Invasive 64.28% 9 35.71% 5 0.052
Non- Invasive 30.76% 8 69.23% 18
Tumor size Micro-Adenoma 30% 3 70% 7 0.023
Macro-adenoma 73.33% 22 26.66% 8
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no significant correlation with the SOX9 level of expression.
Among the invasive GH- secreting tumors 35.71 and
64.28% of tumors expressed low and high SOX9 levels, re-
spectively. However, 69.23% and 30,76% of non-invasive tu-
mors presented low and high SOX9 tumor expression,
respectively. Based on the analysis, the correlation of tumor
invasive features with SOX9 tumor expression was signifi-
cant. Also, tumor size revealed a positive correlation with
SOX9 expression level since 70% of patients with microade-
noma showed low SOX9 expression while 30% of patients
revealed high SOX9 tumor expression. However, 26.66 and
73.33% of patients with macroadenoma showed low and
high SOX9 tumor expression, respectively. Notably, the
Ki67 is a non-histone nuclear protein that accounts as a
marker of cell proliferation that is expressed throughout the
active phase of the cell cycle [31]. In the present study, the
immunoreactivity of the Ki67 was detected and the positivity
was reported as a percentage. Based on the results, none of
the enrolled patients illustrated the Ki67 index higher than
3% while the mean Ki67 proliferation index was 0.4828 ±
0.02953 in non-invasive tumors and 1.468 ± 0.1908 in inva-
sive tumors. The difference in mean Ki67 proliferation index
between invasive and non-invasive GH- secreting pituitary
adenoma was statistically significant (P = 0.001). The correl-
ation between SOX9 expression and the Ki67 proliferation
index in invasive and non-invasive tumors was analyzed
using the Pearson coefficient test which shows no significant
correlation (P = 0.55, P= 0.28, respectively). The regression
analysis of the common variables in GH- secreting pituitary
adenomas demonstrated that the tumor size and tumor in-
vasive feature were significantly valuable in predicting SOX9
tumor expression while the predictive value of patients age,
gender, Growth hormone, and IGF-1 level was not statisti-
cally significant (Table 5).
The SOX9 protein level increased in tumor tissues of GH-
producing pituitary adenomas
Based on our results, SOX9 protein was undetectable in
normal pituitary tissues. In addition, 25% of GH-
producing pituitary tumors showed no expression of
SOX9 while 20 and 55% of tumors revealed a weak and
moderate SOX9 protein expression (Score 1+, Score 2+),
respectively (Table 6). Based on the scoring method, none
of the tumor sections revealed strong and intensive
expression of SOX9 in tumors. The strong expression re-
vealed the pattern that more than 50% of cells in the tissue
section were positively stained with the SOX9 antibody. It
was revealed that all of the macroadenoma tumors
expressed SOX9 protein that amongst, 26.66% of the
macroadenoma tumors expressed weak (Score1+) and
73.33% of macroadenoma tumors expressed moderate
(Score 2+) SOX9 protein. While negative SOX9 protein
expression was detected in 70% of microadenoma tumors
and weak SOX9 expression was detected in 30% of micro-
adenoma tumors (Score 1+). The difference in the SOX9
protein expression level between macro and micro-GH-
secreting pituitary adenoma was statistically significant
(P < 0.0001). Based on our data, 14.28% of invasive GH-
producing pituitary tumors showed weak expression of
SOX9 protein expression (Score 1+), while 85.71% of inva-
sive tumors revealed a moderate level of SOX9 protein
(Score 2+). However, 38.46% of non-invasive GH-
producing pituitary tumors showed no expression of
SOX9 protein while 23.07 and 38.46% of non-invasive tu-
mors showed weak and moderate expression of SOX9
protein (Score 1+, Score 2+, respectively). The difference
in the SOX9 protein expression level between GH-
secreting invasive and non-invasive pituitary adenoma was
statistically significant (P = 0.009). Moreover, the represen-
tative images of SOX9 immunohistochemistry staining in
GH-producing pituitary adenoma tumor tissues are illus-
trated in Fig. 3 and the comparison of SOX9 protein ex-
pression in different types of GH-secreting pituitary
tumors is shown in Fig. 4. Besides, to evaluate the possible
relevance of SOX9 gene expression with SOX9 protein ex-
pression level, a correlation between SOX9 gene expres-
sion in different tumor subtypes and its protein
expression was evaluated and the results are demonstrated
in Table 7. Based on data, the SOX9 gene expression in
GH-secreting pituitary tumors was significantly correlated
with the SOX9 protein level (P = 0.007), also, in the sub-
group of macroadenoma, the SOX9 gene expression was
significantly correlated with its protein expression level
(P = 0.022) while no correlation was observed regarding
the SOX9 gene and protein level in microadenoma group.
Regarding invasive pituitary tumors, it was revealed that
the SOX9 gene expression was significantly correlated
with its protein expression level (P = 0.01), while the
Table 5 The regression model of SOX9 tumor expression in patients with GH-producing pituitary adenoma
Variable (predictors) Standardized Coefficients (Beta) t P value
Patient age 0.200 1.16 0.25
Patient gender −0.322 −1.19 0.064
Tumor size 0.400 3.47 0.001
Tumor invasion 0.350 2.73 0.01
Growth hormone level 0.033 0.21 0.835
IGF-1 hormone level −0.296 −1.85 0.072
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correlation between SOX9 gene and protein expression
was not significant in non-invasive tumors (Table 7).
Discussion
Pituitary adenomas represent around 15% of brain tumors
with the heterogeneous types of neoplasms which the GH-
secreting adenomas account as one of the most prevalent
forms of functional pituitary adenomas [2, 32, 33]. The dy-
namic of pituitary gland cells is tightly related to the body’s
hormonal requirements which steer the vital process like-
wise growth, reproduction, development, and immune re-
sponses [34–37]. In support of this, characterizing the
profile of pituitary adenoma biomarkers might be helpful
both as a point of prognostic and predictive approach also
as a matter of mechanism underlying pituitary tumor gen-
esis although their functional role in pituitary pathogenesis
is debatable. More recently, the relevance of SOX9 to cell
development, growth, and differentiation has received more
attention due to its role to maintain cells in the undifferen-
tiated status [13, 38, 39]. Moreover, it was reported that the
reduction of SOX9 was correlated with a decrease in the
ability of prostate cancer cells to migrate and proliferation
[17]. Additionally, the overexpression of SOX9 in non-
small cell lung cancer was correlated with tumor size and
Table 6 The immunohistochemistry results of SOX9 protein evaluation in patients with GH-producing pituitary adenoma
Groups Expression pattern a P value
Total
number
Score 0 Score 1+ Score 2+
N % N % N %
GH-producing pituitary tumors 40 10 25% 8 20% 22 55%
Macro adenoma 30 0 0 8 26.66% 22 73.33% < 0.0001
Micro adenoma 10 7 70% 3 30% 0 0
Invasive tumors 14 0 0 2 14.28% 12 85.71% 0.009
Non-invasive tumors 26 10 38.46% 6 23.07% 10 38.46%
a The Expression pattern was determined based on the staining intensity of SOX9 antibody that is described in material and methods
Fig. 3 The SOX9 immunohistochemistry. SOX9 differential protein expression was evaluated by immunohistochemistry in GH-secreting tumor
tissues. a Normal pituitary tissue. The score 0; < 5% of neoplastic cells staining, absence of immunoreactivity, × 200., b GH-secreting tumor tissues.
1+; 5–25% of neoplastic cells staining, weak intensity of staining × 200. c GH-secreting tumor tissues. 2+; 26–50% of neoplastic cells staining,
moderate intensity staining, × 200. d GH-secreting tumor tissues.2+; 26–50% of neoplastic cells staining, moderate intensity staining, × 200
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tumor severity [16]. Since the status of SOX9 in pituitary
adenoma tumors was not determined, the expression pat-
tern of this mediator in GH-secreting pituitary adenoma
was investigated in the current study. Based on our data,
the higher expression of SOX9 was detected in tumor tis-
sues comparing to normal pituitary tissues. To the best of
our knowledge, no similar study was implemented in pitu-
itary tumors although its overexpression was reported in
other neoplasms such as melanoma [15] non-small cell
lung cancer [16], prostate cancer [17],and esophageal
squamous cell carcinoma [12]. Due to our data, SOX9 was
expressed more in macroadenoma comparing to tumors
with small size. Also, the relevance of SOX9 with pituitary
tumor size was confirmed by the assessment of SOX9 pro-
tein level in our patients’ tumor sections, and it was re-
vealed that all of the macroadenoma pituitary tumors
expressed SOX9 protein. Accordingly, the invasive GH-
producing pituitary tumors expressed a higher level of
SOX9 comparing to non-invasive tumors also the higher
protein level of SOX9 was observed in invasive tumors.
Based on data, the SOX9 protein level was significantly
correlated with the SOX9 gene expression level in the
Fig. 4 Comparison of SOX9 expression in different types of GH-secreting pituitary tumors using immunohistochemistry. Bar graphs show the
staining intensity of SOX9 in different types of GH-secreting pituitary tumors. Different bar pattern represents the intensity of staining that are
described under the graph. X-axis represents the intensity of staining (a) and type of GH-secreting pituitary tumors (b, c). Y-axis represents the
number of patients positive for a particular type of intensity. a, b, and c showing expression patterns of SOX9 in GH-secreting pituitary tumors,
macroadenoma vs microadenoma, invasive vs. non-invasive tumors, respectively
Table 7 The correlation of SOX9 gene expression with SOX9 protein level in patients with GH-producing pituitary adenoma
Variable Pearson Coefficient test SOX9 protein expression
SOX9 gene expression in Tumor Correlation 0.4248
P-value 0.007
SOX9 gene expression in Macro adenoma Correlation 0.4160
P-value 0.022
SOX9 gene expression in Micro adenoma Correlation 0.0537
P-value 0.8828
SOX9 gene expression in Invasive tumors Correlation 0.6576
P-value 0.0106
SOX9 gene expression in Non-invasive tumors Correlation 0.2959
P-value 0.1421
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subgroup of macroadenoma, microadenoma, and non-
invasive GH-secreting pituitary adenoma. As mentioned
earlier, the Ki67 index accounts as a marker of cell prolif-
eration that is expressed throughout the active phase of
the cell cycle [31]. Based on the European Society of
Endocrinology guidelines, the Ki67 labeling index higher
than 3% can be considered as a positive prognostic marker
in pituitary adenoma. However, the real value of Ki67 and
the use of this criterion as an indicator of pituitary tumor
aggressiveness is controversial and the views in this regard
are vague due to different methodologies and definitions
of tumor progression [40]. The Ki67 proliferation index
shows a significant difference between invasive and non-
invasive GH- secreting pituitary adenomas while it was
not correlated with SOX9 expression. Even though pituit-
ary adenomas account as benign and slow-growing tu-
mors, while the expression profile of SOX9 in these
tumors obeys the same pattern as SOX9 demonstrated in
more malignant solid tumors such as lung and prostate
[16, 17]. In our study, no specific differences were ob-
served in the level of SOX9 expression in male and female
participant’s tumor tissues although the correlation of
SOX9 with gender in pituitary adenomas can be clarified
by further studies. In the present study, no difference was
observed in the level of SOX9 in different age groups,
therefore the association of SOX9 with age in patients
with pituitary tumors cannot be concluded in the study.
Based on recent evidences SOX9 mediates activation of
neurogenin 3 through the Notch pathway which leads to
pancreatic endocrine differentiation [14]. Besides, exogen-
ous SOX9 induces chondrogenesis, differentiation, and
proliferation of adipose-derived mesenchyme stem cells as
well as nervous system, lung, and heart organogenesis
[41]. Besides its role in inducing cell differentiation to the
specific lineage, SOX9 can maintain cells in the undiffer-
entiated status as it is observed in suppressing epidermal
differentiation in hair follicle stem cells [42]. Also, it was
shown that SOX9 + cells derived from human hepatocel-
lular carcinoma (HCC) were highly proliferative and able
to self-renewal which makes them an appropriate CSC
marker in HCC [43]. In line with the evidences, the over-
expression of SOX9 in GH- secreting pituitary tumors un-
ravel the possible contribution of this regulatory transcrip-
tion factor in pituitary tumor formation also
differentiation to GH secreting cells however this claim
should be clarified by more mechanistic studies. As it was
observed from our results, SOX9 over-expressed in GH-
secreting tumor tissues and the differences in its expres-
sion level were significant between tumor subtypes such
as macro adenoma tumors and invasive GH-producing pi-
tuitary tumors. However, based on the nature of pituitary
adenoma tumors which are mainly benign and the limited
number of participants with invasive tumors in our study,
extending and investigating the role of SOX9 in GH-
producing pituitary adenoma tumorigenesis in more di-
verse patients are recommended.
Conclusions
Our study provides first data regarding the status of
SOX9 as an appealing marker in patients with GH-
secreting pituitary adenoma. Due to our data, the over-
expression of the SOX9 gene level was observed in pitu-
itary tumor tissues in comparison to normal tissues
which was associated with an elevated level of SOX9
protein in tumor tissues. In GH-secreting pituitary
tumor tissues as prevalent pituitary tumors, the in-
creased level of SOX9 was observed in tumors with big-
ger in size and invasive features which is in line with the
impressive role of SOX9 in cell proliferation and inva-
sion. The presence and overproduction of SOX9 as a
pivotal stem cell marker in GH-secreting pituitary aden-
oma may highlight the effective impact of stem cells in
the pituitary gland which might facilitate organ regener-
ation also cell differentiation to hormone-secreting cells.
Also, it might provide shreds of evidence regarding the
possibility of SOX9 involvement in pituitary adenoma
tumor formation that can delineate the GH-secreting pi-
tuitary adenoma underlying molecular mechanism.
Abbreviations
SOX9: Sex-determining region Y-box 9; IGF-I: Insulin-like growth factor-1;
GH: Growth hormone; CSC: Cancer stem cell; PMCs: Progenitor mesenchymal
cells; EPCs: Endothelial progenitor cells; SSTR: Somatostatin receptors;
ETSS: Endoscopic transnasal transsphenoidal surgery; LMO: Legal Medicine
Organization; DAB: 3, 3′-diaminobenzidine; HCC: Human hepatocellular




FISH carried out the experiments, performed sample collection, MGH
provided tumor tissues, AA provided normal tissues, MEK and MI provided
patient’s information and contributed to clinical interpretation, MP
contributed to immunohistochemistry interpretation, MN contributed to
scientific interpretation, VS contributed to data analysis, scientific
interpretation and writing manuscript, MTY designed the study, performed
data analysis and wrote the manuscript. The author(s) read and approved
the final manuscript.
Authors’ information
FISH (MSc of Clinical Biochemistry), MGH (Assistant Professor of
Interventional Neurosurgery), VS (Associate Professor of Medical Virology), AA
(Vice President of research at Iranian Legal Medicine Organizations), MEK
(Professor of Endocrinology & Metabolism), MI (Assistant Professor of
Endocrinology & Metabolism) MN (Associate Professor of Clinical
Biochemistry), MP (Assistant Professor of pathology), MTY (Associate
Professor of Clinical Biochemistry). The author(s) read and approved the final
manuscript.
Funding
This work was financially supported by the Iran University of Medical
Sciences (Grant Number: 96–04–30-32417).
Availability of data and materials
All data generated or analyzed during this study and supporting our findings
are included and can be found in the manuscript. The raw data can be
provided by the corresponding author on reasonable request.
Shirian et al. BMC Endocrine Disorders           (2021) 21:50 Page 10 of 12
Declarations
Ethics approval and consent to participate
The project was ethically approved by the ethics committee of the Vice
president of research of Iran University of Medical Sciences with ethics
committee code: IR.IUMS.FMD.REC 1396.3184140/01/6931). All patients were
informed before surgery and they were provided with written informed
consent for participation. In the consent form, they were informed that their
tumor tissues will be collected and used for this study. Following their
agreement to participate in the study and signed consent form, they were
included in the survey. For each patient the written informed consent is
available. The healthy pituitary tissues were collected from the Legal
Medicine Organization (LMO), Tehran, Iran following the required ethical
approval which was needed for the organization. The first-degree relatives of
deceased individuals were informed and provided with a written consent
form, indicating a collection of normal pituitary autopsies and following their
agreement and signed consent form, the normal pituitary tissues were col-
lected. Also, all methods were carried out under relevant guidelines and
regulations.
Consent for publication
The consent for publication is not required since no personal or identifying
information of participants are contained within the manuscript or
supplementary materials.
Competing interests
The authors declare that there is no conflict of interest.
Author details
1Department of Biochemistry, School of Medicine, Iran University of Medical
Sciences, Tehran, Iran. 2Endocrine Research Center, Institute of Endocrinology
and Metabolism, Iran University of Medical Sciences (IUMS), Tehran, Iran.
3Firozgar Hospital, Pathology Department, Iran University of Medical
Sciences, Tehran, Iran. 4Iranian Legal Medicine Organizations, Tehran, Iran.
5Department of Virology, School of Public Health, Tehran University of
Medical Sciences, Tehran, Iran.
Received: 20 October 2020 Accepted: 10 March 2021
References
1. Barbieri F, Thellung S, Wurth R, Gatto F, Corsaro A, Villa V, Nizzari M,
Albertelli M, Ferone D, Florio T. Emerging targets in pituitary adenomas: role
of the CXCL12/CXCR4-R7 system. Int J Endocrinol. 2014;2014:753524.
2. Lavrentaki A, Paluzzi A, Wass JA, Karavitaki N. Epidemiology of acromegaly:
review of population studies. Pituitary. 2017;20(1):4–9. https://doi.org/10.1
007/s11102-016-0754-x.
3. Mazziotti G, Lania A, Canalis E. Management of endocrine disease: bone
disorders associated with acromegaly: mechanisms and treatment. Eur J
Endocrinol. 2019;181(2):R45–56. https://doi.org/10.1530/EJE-19-0184.
4. Abucham J, Bronstein MD, Dias ML. Management of endocrine disease:
acromegaly and pregnancy: a contemporary review. Eur J Endocrinol. 2017;
177(1):R1–r12. https://doi.org/10.1530/EJE-16-1059.
5. Keskin FE, Yetkin DO, Ozkaya HM, Haliloglu O, Sadri S, Gazioglu N, Tanriover
N, Ak H, Hatipoglu E, Kadioglu P. The problem of unrecognized acromegaly:
surgeries patients undergo prior to diagnosis of acromegaly. J Endocrinol
Investig. 2015;38(6):695–700. https://doi.org/10.1007/s40618-015-0245-3.
6. Florea V, Majid SS, Kanashiro-Takeuchi RM, Cai RZ, Block NL, Schally AV, Hare
JM, Rodrigues CO. Agonists of growth hormone-releasing hormone
stimulate self-renewal of cardiac stem cells and promote their survival. Proc
Natl Acad Sci U S A. 2014;111(48):17260–5. https://doi.org/10.1073/pnas.142
0375111.
7. Caffarini M, Orciani M, Trementino L, Di Primio R, Arnaldi G. Pituitary
adenomas, stem cells, and cancer stem cells: what's new? J Endocrinol
Investig. 2018;41(7):745–53. https://doi.org/10.1007/s40618-017-0803-y.
8. Haston S, Manshaei S, Martinez-Barbera JP. Stem/progenitor cells in pituitary
organ homeostasis and tumourigenesis. J Endocrinol. 2018;236(1):R1–r13.
https://doi.org/10.1530/JOE-17-0258.
9. Orciani M, Davis S, Appolloni G, Lazzarini R, Mattioli-Belmonte M, Ricciuti RA,
Boscaro M, Di Primio R, Arnaldi G. Isolation and characterization of
progenitor mesenchymal cells in human pituitary tumors. Cancer Gene
Ther. 2015;22(1):9–16. https://doi.org/10.1038/cgt.2014.63.
10. Mirzaei A, Tavoosidana G, Rad AA, Rezaei F, Tavakoli-Yaraki M, Kadijani AA,
Khalili E, Madjd Z. A new insight into cancer stem cell markers: could local
and circulating cancer stem cell markers correlate in colorectal cancer?
Tumour Biol. 2016;37(2):2405–14. https://doi.org/10.1007/s13277-015-3989-7.
11. Orciani M, Caffarini M, Sorgentoni G, Ricciuti RA, Arnaldi G, Di Primio R.
Effects of somatostatin and its analogues on progenitor mesenchymal cells
isolated from human pituitary adenomas. Pituitary. 2017;20(2):251–60.
https://doi.org/10.1007/s11102-016-0770-x.
12. Hong Y, Chen W, Du X, Ning H, Chen H, Shi R, Lin S, Xu R, Zhu J, Wu S,
et al. Upregulation of sex-determining region Y-box 9 (SOX9) promotes cell
proliferation and tumorigenicity in esophageal squamous cell carcinoma.
Oncotarget. 2015;6(31):31241–54. https://doi.org/10.18632/oncotarget.5160.
13. Antoniou A, Raynaud P, Cordi S, Zong Y, Tronche F, Stanger BZ, Jacquemin
P, Pierreux CE, Clotman F, Lemaigre FP. Intrahepatic bile ducts develop
according to a new mode of tubulogenesis regulated by the transcription
factor SOX9. Gastroenterology. 2009;136(7):2325–33. https://doi.org/10.1053/
j.gastro.2009.02.051.
14. Kawaguchi Y. Sox9 and programming of liver and pancreatic progenitors. J
Clin Invest. 2013;123(5):1881–6. https://doi.org/10.1172/JCI66022.
15. Rao P, Fuller GN, Prieto VG. Expression of Sox-9 in metastatic melanoma--a
potential diagnostic pitfall. Am J Dermatopathol. 2010;32(3):262–6. https://
doi.org/10.1097/DAD.0b013e3181b7fc8d.
16. Chen W, Zhao W, Chen S, Zhang L, Guo Z, Wang L, Wang J, Wan Z, Hong Y,
Yu L. Expression and correlation of MALAT1 and SOX9 in non-small cell
lung cancer. Clin Respir J. 2018;12(7):2284–91. https://doi.org/10.1111/crj.12
906.
17. Xi M, Wan S, Hua W, Zhou Y, Jiang W, Hu J. Correlation of SOX9 and NM23
genes with the incidence and prognosis of prostate cancer. Oncol Lett.
2019;17(2):2296–302. https://doi.org/10.3892/ol.2018.9828.
18. Maneix L, Servent A, Poree B, Ollitrault D, Branly T, Bigot N, Boujrad N,
Flouriot G, Demoor M, Boumediene K, et al. Up-regulation of type II
collagen gene by 17beta-estradiol in articular chondrocytes involves Sp1/3,
Sox-9, and estrogen receptor alpha. J Mole Med. 2014;92(11):1179–200.
19. Lynn FC, Smith SB, Wilson ME, Yang KY, Nekrep N, German MS. Sox9
coordinates a transcriptional network in pancreatic progenitor cells. Proc
Natl Acad Sci U S A. 2007;104(25):10500–5. https://doi.org/10.1073/pnas.
0704054104.
20. Vankelecom H, Roose H. The stem cell connection of pituitary tumors. Front
Endocrinol. 2017;8:339. https://doi.org/10.3389/fendo.2017.00339.
21. Barooni AB, Ghorbani M, Salimi V, Alimohammadi A, Khamseh ME, Akbari H,
Imani M, Nourbakhsh M, Sheikhi A, Shirian FI, Ameri M, Tavakoli-Yaraki M.
Up-regulation of 15-lipoxygenase enzymes and products in functional and
non-functional pituitary adenomas. Lipids Health Dis. 2019;18(1):152. https://
doi.org/10.1186/s12944-019-1089-1.
22. Akbari N, Ghorbani M, Salimi V, Alimohammadi A, Khamseh ME, Akbari H,
Nourbakhsh M, Sheikhi A, Taghavi SF, Tavakoli-Yaraki M. Cyclooxygenase
enzyme and PGE2 expression in patients with functional and non-functional
pituitary adenomas. BMC Endocr Disord. 2020;20(1):39. https://doi.org/10.11
86/s12902-020-0515-8.
23. Han X, Geng X, Li Z, Chen Z, Liu Y, Liu P, Wang Q, Li C, Ai D, Li Z. The
relationship between Phospho-p38, matrix metalloproteinase 9, and major
histocompatibility complex class I chain-related molecule a expression in
pituitary adenomas demonstrates a new mechanism of pituitary adenoma
immune escape. World Neurosurg. 2019;123:e116–24. https://doi.org/10.101
6/j.wneu.2018.11.077.
24. Vaitkiene P, Valiulyte I, Glebauskiene B, Liutkeviciene R. N-myc downstream-
regulated gene 2 (NDRG2) promoter methylation and expression in
pituitary adenoma. Diagn Pathol. 2017;12(1):33. https://doi.org/10.1186/s13
000-017-0622-7.
25. Yu C, Li J, Sun F, Cui J, Fang H, Sui G. Expression and clinical significance of
miR-26a and pleomorphic adenoma gene 1 (PLAG1) in invasive pituitary
adenoma. Med Sci Monit. 2016;22:5101–8. https://doi.org/10.12659/MSM.
898908.
26. Takei M, Suzuki M, Kajiya H, Ishii Y, Tahara S, Miyakoshi T, Egashira N,
Takekoshi S, Sanno N, Teramoto A, Osamura RY. Immunohistochemical
detection of somatostatin receptor (SSTR) subtypes 2A and 5 in pituitary
adenoma from acromegalic patients: good correlation with preoperative
response to octreotide. Endocr Pathol. 2007;18(4):208–16. https://doi.org/1
0.1007/s12022-007-9004-0.
Shirian et al. BMC Endocrine Disorders           (2021) 21:50 Page 11 of 12
27. DeRycke MS, Andersen JD, Harrington KM, Pambuccian SE, Kalloger SE,
Boylan KL, Argenta PA, Skubitz AP. S100A1 expression in ovarian and
endometrial endometrioid carcinomas is a prognostic indicator of relapse-
free survival. Am J Clin Pathol. 2009;132(6):846–56. https://doi.org/10.1309/A
JCPTK87EMMIKPFS.
28. Hajian-Tilaki K. Receiver operating characteristic (ROC) curve analysis for
medical diagnostic test evaluation. Caspian J Intern Med. 2013;4(2):627–35.
29. Obuchowski NA, Bullen JA. Receiver operating characteristic (ROC) curves:
review of methods with applications in diagnostic medicine. Phys Med Biol.
2018;63(7):07tr01.
30. Hoppe FM, Hoppe DJ, Walter SD. Explaining odds ratios as conditional risk
ratios. J Clin Epidemiol. 2018;97:123–4. https://doi.org/10.1016/j.jclinepi.201
7.10.009.
31. Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index
and p53 expression in predicting progression of pituitary adenomas. Hum
Pathol. 2008;39(5):758–66. https://doi.org/10.1016/j.humpath.2007.10.004.
32. Cuevas-Ramos D, Fleseriu M. Pasireotide: a novel treatment for patients with
acromegaly. Drug Design Dev Ther. 2016;10:227–39.
33. Brown R, Imran SA, Wilkinson M. Lipopolysaccharide (LPS) stimulates
adipokine and socs3 gene expression in mouse brain and pituitary gland
in vivo, and in N-1 hypothalamic neurons in vitro. J Neuroimmunol. 2009;
209(1–2):96–103. https://doi.org/10.1016/j.jneuroim.2009.02.001.
34. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and
potential therapeutic applications of growth hormone-releasing hormone
agonists. Endocrinology. 2019;160(7):1600–12. https://doi.org/10.1210/en.201
9-00111.
35. Carreno G, Gonzalez-Meljem JM, Haston S, Martinez-Barbera JP. Stem cells
and their role in pituitary tumorigenesis. Mol Cell Endocrinol. 2017;445:27–
34. https://doi.org/10.1016/j.mce.2016.10.005.
36. Cox B, Roose H, Vennekens A, Vankelecom H. Pituitary stem cell regulation:
who is pulling the strings? J Endocrinol. 2017;234(3):R135–r158. https://doi.
org/10.1530/JOE-17-0083.
37. Kano M, Suga H, Kasai T, Ozone C, Arima H. Functional pituitary tissue
generation from human embryonic stem cells. Curr Protoc Neurosci. 2018;
83(1):e48. https://doi.org/10.1002/cpns.48.
38. Darido C, Buchert M, Pannequin J, Bastide P, Zalzali H, Mantamadiotis T,
Bourgaux JF, Garambois V, Jay P, Blache P, Joubert D, Hollande F. Defective
claudin-7 regulation by Tcf-4 and sox-9 disrupts the polarity and increases
the tumorigenicity of colorectal cancer cells. Cancer Res. 2008;68(11):4258–
68. https://doi.org/10.1158/0008-5472.CAN-07-5805.
39. Aleshcheva G, Wehland M, Sahana J, Bauer J, Corydon TJ, Hemmersbach R,
Frett T, Egli M, Infanger M, Grosse J, Grimm D. Moderate alterations of the
cytoskeleton in human chondrocytes after short-term microgravity
produced by parabolic flight maneuvers could be prevented by up-
regulation of BMP-2 and SOX-9. FASEB J. 2015;29(6):2303–14. https://doi.
org/10.1096/fj.14-268151.
40. Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V,
Trouillas J, Dekkers OM. European Society of Endocrinology Clinical Practice
Guidelines for the management of aggressive pituitary tumours and
carcinomas. Eur J Endocrinol. 2018;178(1):G1–g24. https://doi.org/10.1530/
EJE-17-0796.
41. Zhang Y, Tang CL, Chen WJ, Zhang Q, Wang SL. Dynamic compression
combined with exogenous SOX-9 promotes chondrogenesis of adipose-
derived mesenchymal stem cells in PLGA scaffold. Eur Rev Med Pharmacol
Sci. 2015;19(14):2671–8.
42. Kadaja M, Keyes BE, Lin M, Pasolli HA, Genander M, Polak L, Stokes N, Zheng
D, Fuchs E. SOX9: a stem cell transcriptional regulator of secreted niche
signaling factors. Genes Dev. 2014;28(4):328–41. https://doi.org/10.1101/ga
d.233247.113.
43. Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, Katayama H,
Yoshitoshi EY, Ogiso S, Kita S, Yasuda K, Fukumitsu K, Komori J, Hatano E,
Kawaguchi Y, Uemoto S. SOX9 is a novel cancer stem cell marker
surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep.
2016;6(1):30489. https://doi.org/10.1038/srep30489.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Shirian et al. BMC Endocrine Disorders           (2021) 21:50 Page 12 of 12
